Gilead (GILD) Issues Strong '7977 Update, Shares Move Higher
Tweet Send to a Friend
Get Alerts GILD Hot Sheet
Down)
Trade GILD Now!
Shares of Gilead Sciences, Inc. (Nasdaq: GILD) are moving higher Friday following positive data related to its experimental hepatitis C (HCV) treatments.
On the company's fourth-quarter earnings conference call late Thursday, Gilead's scientific chief Norbert Bischofberger said trials of PSI-7977 in patients with genotype 1 HCV showed no signs of the virus after being on the drug for four weeks.
PSI-7977 was said to cure patients with genotypes 2 and 3, according to earlier studies.
Competitors in the field include Merck (NYSE: MRK), Vertex Pharma (NYSE: VRTX), Bristol-Myers Squibb (NYSE: BMY), Idenix Pharma (Nasdaq: IDIX) and Achillion Pharma (Nasdaq: ACHN).
A number of analysts issued comments on Gilead following the call. For more color, click here.
Gilead shares last traded at $54.40, up 10.3 percent from Thursday's close.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
On the company's fourth-quarter earnings conference call late Thursday, Gilead's scientific chief Norbert Bischofberger said trials of PSI-7977 in patients with genotype 1 HCV showed no signs of the virus after being on the drug for four weeks.
PSI-7977 was said to cure patients with genotypes 2 and 3, according to earlier studies.
Competitors in the field include Merck (NYSE: MRK), Vertex Pharma (NYSE: VRTX), Bristol-Myers Squibb (NYSE: BMY), Idenix Pharma (Nasdaq: IDIX) and Achillion Pharma (Nasdaq: ACHN).
A number of analysts issued comments on Gilead following the call. For more color, click here.
Gilead shares last traded at $54.40, up 10.3 percent from Thursday's close.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
- Domino's Pizza (DPZ) Added to S&P MidCap 400, Cynosure (CYNO) to S&P SmallCap 600
- NetApp (NTAP) Tops Q4 EPS by 1c; Boosts Buyback, Plans Job Cuts, Initiates Dividend
Create E-mail Alert Related Categories
Corporate News, Insiders' BlogRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
